VANCOUVER, Washington, June 08, 2020 (GLOBE NEWSWI
Post# of 148181
(Total Views: 677)
Posted On: 07/10/2020 9:11:34 AM
Re: Rubraquercus #42072
VANCOUVER, Washington, June 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (FDA) advised the Company, subject to its ongoing review, it could receive its “PDUFA date” on July 10, 2020.
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (FDA) advised the Company, subject to its ongoing review, it could receive its “PDUFA date” on July 10, 2020. 
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼